Literature DB >> 24286219

Impact of epicardial ablation of concomitant atrial fibrillation on atrial natriuretic peptide levels and atrial function in 6 months follow-up: does preoperative ANP level predict outcome of ablation?

Marek Pizon1, Norbert Friedel, Monika Pizon, Miriam Freundt, Michael Weyand, Richard Feyrer.   

Abstract

BACKGROUND: Epicardial ablation concomitant to cardiac surgery is an easy and safe approach to treat atrial fibrillation (AF), but its efficacy in longstanding persistent (LsPe) AF remains intermediate. Although larger left atrial size has been associated with worse outcome after ablation, biochemical predictors of success are not well established. The aim of this study was to evaluate relationship between biochemical marker, echo-characteristic and cardiac rhythm in 6 months follow-up after epicardial ultrasound (HIFU) ablation.
METHODS: We included 78 consecutive patients, who underwent elective cardiac surgery. 42 patients with AF (11.9% paroxysmal, 23.8% persistent, 64.3% LsPeAF) underwent concomitant HIFU ablation (AF ablation group), 16 with AF underwent cardiac surgery without ablation (AF control) and 20 had preoperatively normal sinus rhythm (SR control). We measured plasma ANP secretion before, on postoperative day (POD) 1, POD 7 as well as 3 and 6 months after surgery. Moreover, we estimated cardiac rhythm and atrial mechanical function by Atrial Filling Fraction (AFF) and A-wave velocity in follow-up.
RESULTS: Baseline ANP levels were higher in patients with LsPeAF, as compared to the paroxysmal and permanent AF and to the SR control group. Patients with LsPeAF (n = 27) who converted to SR had preoperatively smaller left atrial diameter (LAD) and LA area (p < 0.05) and higher ANP level (p = 0.009) than those who remained in AF at 6 months after ablation. Multivariate regression analysis revealed that only preoperative ANP level was an independent predictor of cardiac rhythm after ablation. Patients with LsPeAF and preoperative ANP >7.5 nmol/l presented with SR in 80%, in contrast to those with ANP <7.5 nmol/l who converted to SR in 20%. We detected gradual increase of AFF and A-velocity at 6 months after ablation (p < 0.05) solely in AF ablation group. ANP levels were increased on POD 1 in ablation group (p < 0.05), without changes in further follow-up.
CONCLUSION: Our results indicate that preoperative ANP levels may be a new biochemical predictor of successful epicardial ablation in patients with concomitant LsPeAF. HIFU ablation caused a significant improvement of atrial mechanical function and gradual increase of AFF and did not associate with alteration of atrial endocrine secretion at 6 months follow-up.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24286219      PMCID: PMC3892101          DOI: 10.1186/1749-8090-8-218

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  36 in total

1.  Preservation of the right atrial appendage improves reduced plasma atrial natriuretic peptide levels after the maze procedure.

Authors:  F Yoshihara; T Nishikimi; Y Sasako; J Kobayashi; Y Kosakai; R Hattori; T Horio; S Kitamura; H Matsuo; T Ohe; K Kangawa
Journal:  J Thorac Cardiovasc Surg       Date:  2000-04       Impact factor: 5.209

2.  Prediction of atrial fibrillation after coronary artery bypass grafting by measuring atrial peptide levels and preoperative atrial dimensions.

Authors:  T Hakala; A Hedman; A Turpeinen; R Kettunen; O Vuolteenaho; M Hippeläinen
Journal:  Eur J Cardiothorac Surg       Date:  2002-12       Impact factor: 4.191

3.  The importance of assessing the fit of logistic regression models: a case study.

Authors:  D W Hosmer; S Taber; S Lemeshow
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

4.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

Authors:  Simon Stewart; Carole L Hart; David J Hole; John J V McMurray
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

5.  Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure.

Authors:  Fumiki Yoshihara; Toshio Nishikimi; Yoshikado Sasako; Jun Hino; Junjiro Kobayashi; Kenji Minatoya; Ko Bando; Yoshio Kosakai; Takeshi Horio; Shin-ichi Suga; Yuhei Kawano; Hiroaki Matsuoka; Chikao Yutani; Hisayuki Matsuo; Soichiro Kitamura; Tohru Ohe; Kenji Kangawa
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

6.  Does preoperative atrial fibrillation reduce survival after coronary artery bypass grafting?

Authors:  Mohammed A Quader; Patrick M McCarthy; A Marc Gillinov; Joan M Alster; Delos M Cosgrove; Bruce W Lytle; Eugene H Blackstone
Journal:  Ann Thorac Surg       Date:  2004-05       Impact factor: 4.330

7.  Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation.

Authors:  Beata Wozakowska-Kapłon; Grzegorz Opolski
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

8.  Effect of maze procedure in patients with atrial fibrillation undergoing valve replacement.

Authors:  Ko Bando; Junjiro Kobayashi; Yoshikado Sasako; Osamu Tagusari; Kazuo Niwaya; Soichiro Kitamura
Journal:  J Heart Valve Dis       Date:  2002-09

9.  Pulmonary vein isolation by microwave energy ablation in patients with permanent atrial fibrillation.

Authors:  Michael Knaut; Sems Malte Tugtekin; Klaus Matschke
Journal:  J Card Surg       Date:  2004 May-Jun       Impact factor: 1.620

10.  [Influence of cardiopulmonary bypass (CPB) on the natriuretic peptides ANP and BNP. A comparison between long and short duration of CPB and off pump surgery].

Authors:  S N Piper; B Kumle; K D Röhm; S W Suttner; J Lang; M Blome; J Boldt
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2003-07       Impact factor: 0.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.